8-K: Milestone Pharma: EMA Accepts Etripamil PSVT Application

Milestone Pharmaceuticals announced the European Medicines Agency accepted its Marketing Authorization Application for etripamil nasal spray for PSVT, with a decision expected by Q1 2027.

Summary

• The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) from Milestone Pharmaceuticals Inc. for etripamil nasal spray.
• The MAA seeks approval for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) outside of the healthcare setting.
• A decision on approval from the EMA is expected by the first quarter of 2027.
• Etripamil, conditionally branded TACHYMIST in Europe, is an investigational, novel calcium channel blocker designed for patient self-administration.
• The MAA submission is supported by a robust clinical trial program, including data from over 1,800 participants and 2,000 PSVT episodes.
• The pivotal Phase 3 RAPID trial demonstrated that 64% of etripamil users converted to sinus rhythm within 30 minutes, compared to 31% on placebo (HR=2.62; p<0.001).
• The median time to conversion was 17 minutes for etripamil, significantly faster than 54 minutes for placebo.
• Etripamil is already approved by the U.S. FDA under the brand name CARDAMYST for acute symptomatic PSVT episodes in adults.
• Approximately two million people in Europe are diagnosed with PSVT, a condition characterized by sudden onset rapid heartbeats.

Sentiment

Score: 8

Explanation: The EMA's acceptance of the MAA is a significant positive development, indicating strong progress towards market entry in Europe for a drug with robust clinical data and prior FDA approval. This addresses a substantial unmet medical need and could provide a new revenue stream, enhancing the company's market position and growth prospects.

Positives

• EMA acceptance of the Marketing Authorization Application is a significant regulatory milestone, advancing etripamil towards potential market entry in Europe.
• Etripamil (TACHYMIST) has the potential to be the first approved patient self-administered therapy for PSVT in Europe, addressing a significant unmet medical need for approximately two million patients.
• The MAA is supported by strong efficacy and safety data from a robust clinical program, including the successful Phase 3 RAPID trial.
• Clinical studies showed etripamil users were two times more likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster compared with placebo.
• In the RAPID trial, 64% of participants self-administering etripamil converted to sinus rhythm within 30 minutes, compared to 31% on placebo (HR=2.62; p<0.001).
• Etripamil demonstrated a rapid median time to conversion of 17 minutes, versus 54 minutes for placebo.
• A consistent safety profile and treatment effects were observed across all subgroups, including participants concurrently on beta blockers or calcium channel blockers.
• Adverse events were mild-to-moderate and transient, with less than 2% of trial participants discontinuing therapy due to adverse events.
• Etripamil is already FDA approved in the U.S. as CARDAMYST, providing strong validation of its profile.

Negatives

• Etripamil is still an investigational drug in Europe, and approval by the EMA is not guaranteed.
• The approval decision is not expected until the first quarter of 2027, indicating a waiting period.
• Potential adverse events, though mild-to-moderate and transient, include local-site nasal discomfort, nasal congestion, rhinorrhea, throat irritation, and epistaxis.

Risks

• Uncertainty regarding whether Milestone's future interactions with the EMA will have satisfactory outcomes.
• Uncertainty whether and when, if at all, Milestone's MAA for etripamil will be approved by the EMA.
• Risks and uncertainty related to the timing of initiation, enrollment, completion, evaluation, and results of Milestone's clinical trials.
• Risks and uncertainty related to the complexity inherent in cleaning, verifying, and analyzing trial data.
• Uncertainty whether clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine, and ongoing disputes in the Middle East.
• Overall fluctuations in the financial markets in the United States and abroad.
• Risks related to pandemics and public health emergencies.
• Risks related to the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate.

Future Outlook

A decision on EMA approval for etripamil nasal spray (TACHYMIST) is expected by the first quarter of 2027. If approved, etripamil is anticipated to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting in Europe, addressing a market of approximately two million people. Etripamil is also in Phase 2 development for PSVT in pediatric patients and Phase 3 development for acute treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults.

Management Comments

• "Following guidance from the EMA, this MAA incorporates the global clinical data package that supported the U.S. Food and Drug Administration approval of etripamil for the treatment of PSVT." Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.
• "TACHYMIST could become the first approved patient self-administered therapy representing a meaningful step forward in patient care for the approximately two million people suffering from PSVT in Europe." Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.

Industry Context

The acceptance of the Marketing Authorization Application for etripamil nasal spray by the EMA positions Milestone Pharmaceuticals to potentially introduce a groundbreaking, self-administered treatment for PSVT into the European market. This could significantly transform the current treatment landscape, which often necessitates emergency department visits or invasive procedures, by empowering patients with a convenient, on-demand therapy. Given etripamil's prior FDA approval in the U.S. as CARDAMYST, the drug carries a strong validation of its efficacy and safety, suggesting a robust competitive advantage if it secures European approval.

Comparison to Industry Standards

• Etripamil offers a significant advancement over current PSVT treatment options, which frequently involve burdensome and costly trips to the emergency department or invasive cardiac ablation procedures.
• In the pivotal RAPID Phase 3 trial, etripamil demonstrated a 64% conversion rate to sinus rhythm within 30 minutes, substantially outperforming the 31% observed with placebo, indicating superior efficacy.
• The median time to conversion for etripamil was 17 minutes, which is considerably faster than the 54 minutes for placebo, highlighting its rapid therapeutic action.
• The self-administered nasal spray delivery method is a novel approach, providing patients with convenience and a sense of control over their condition that is not typically available with existing treatments.

Stakeholder Impact

• Shareholders: Positive impact due to the potential for market expansion into Europe and increased revenue streams if etripamil is approved, reducing regulatory risk for European market entry.
• Patients (PSVT sufferers in Europe): Highly positive impact by offering a convenient, self-administered, rapid-response treatment option, potentially reducing the need for emergency department visits and improving quality of life.
• Healthcare Providers: Provides a new, effective treatment option for PSVT, enabling on-demand care and patient self-management, which could potentially ease the burden on healthcare systems.

Next Steps

• EMA review of the Marketing Authorization Application for etripamil nasal spray.
• Anticipated EMA decision on approval by the first quarter of 2027.
• Continued Phase 2 development of etripamil for PSVT in pediatric patients.
• Continued Phase 3 development of etripamil for acute treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults.

Key Dates

Recommendation

The EMA's acceptance of the Marketing Authorization Application for etripamil nasal spray is a major de-risking event for Milestone Pharmaceuticals, opening up a significant new market in Europe for a product that is already FDA-approved and backed by robust clinical data. The potential to be the first self-administered therapy for PSVT in Europe, addressing a market of two million patients, represents a substantial growth opportunity. While approval is not guaranteed, the strong clinical package and prior U.S. approval significantly increase the probability of success. This development, coupled with ongoing trials for other indications, positions the company for strong future growth and makes the stock a strong buy for investors seeking exposure to innovative cardiovascular therapies.

Keywords

Milestone Pharmaceuticals, Etripamil, TACHYMIST, CARDAMYST, PSVT, Paroxysmal Supraventricular Tachycardia, EMA, European Medicines Agency, Marketing Authorization Application, Nasal Spray, Cardiovascular Medicine, Calcium Channel Blocker, Biopharmaceutical, RAPID trial, FDA approval